Renhe Yikang：Topamax Topiramate was approved for marketing and deemed to have passed the consistency evaluation.
Roche：Giredestrant receives FDA filing acceptance
Boundless Bio：Bepirovirsen was not approved by the NMPA recently.
Hengrui ：HRS-7535 for Phase III Clinical Trial in Chronic Kidney Disease
Roche：Gazyva® Obinutuzumab Granted Priority Review
Sichuan Biokin：BL-M14D1 initiates its first global Phase III trial.
Qihan Biotech：In vivo CAR-T clinical data were disclosed by Qihan Biotech.
Lupeng：Rocbrutinib received marketing approval
Jiangsu Vcare：VC004 injection approved via priority review.
Otsuka Pharmaceutical：VoyxactSibeprenlimab was approved through the priority review process.
